ArticleFrontiers in oncology2026
Subcutaneous hematoma of the lower abdomen and perineum following transperineal prostate biopsy: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is the most common malignant neoplasm of the urogenital system, with definitive diagnosis currently relying exclusively on prostate biopsy. Although the transperineal approach is associated with a lower incidence of perioperative complications, postoperative subcutaneous hematoma in the perineal region may be overlooked due to its anatomically concealed presentation, leading to delayed clinical attention. This report presents a case of extensive subcutaneous hematoma involving the lower abdomen and perineum following transperineal prostate biopsy in a patient diagnosed with PCa. Prompt management with prostatic artery angiography and superselective prostatic artery embolization, supplemented by endocrine therapy, resulted in rapid resolution of the hematoma. At three-month follow-up, tumor biomarkers remained stable, and key biochemical parameters had returned to pre-biopsy baseline levels, indicating favorable disease control and recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.